U.S. Vascular Graft Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Vascular Graft Market
- ✓Market Size 2024: USD 1.12 billion
- ✓Market Size 2032: USD 1.78 billion
- ✓CAGR: 6.0%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Lock Supply Before Tariffs: Procurement directors at U.S. hospital systems should renegotiate ePTFE and Dacron graft contracts with Gore or Terumo Aortic before the third quarter of 2026, fixing prices ahead of any Section 232 medical device tariffs.
Vascular Grafts in the United States: Market Overview
The U.S. vascular graft market was valued at USD 1.12 billion in 2024 and is forecast to reach USD 1.78 billion by 2032, accounting for roughly 40 percent of global demand. Most synthetic aortic and peripheral grafts are regulated by the Food and Drug Administration as Class III implantable devices under the Federal Food, Drug, and Cosmetic Act, requiring premarket approval before commercial sale. This regulatory gate has concentrated supply among a small number of manufacturers able to fund multi-year clinical programs.
Private industry leads product design and manufacturing. W. L. Gore and Associates pioneered expanded PTFE grafts, while Terumo Aortic and Artivion compete in woven polyester and tissue-based aortic products. Government leads demand. Centers for Medicare and Medicaid Services (CMS) payment rules under MS-DRG and the Outpatient Prospective Payment System determine which graft types hospitals can afford, and the Department of Veterans Affairs buys through national contracts managed by its National Acquisition Center.
Policy-Driven Growth in Vascular Grafts in the United States
Three mechanisms drive demand. First, the CMS Inpatient Prospective Payment System grants new technology add-on payments (NTAP) of up to 65 percent of device cost for qualifying grafts under annual IPPS final rules, reducing financial risk for hospitals adopting endovascular and hybrid designs. Second, the CMS ESRD Prospective Payment System and the Kidney Care Choices model reward dialysis providers for maintaining hemodialysis patients, and access grafts serve patients whose veins cannot sustain a fistula.
Third, the Medical Device User Fee Amendments under MDUFA V, covering fiscal years 2023 through 2027, commit FDA to decide 90 percent of original premarket approval applications within 180 review days. Faster clearance shortens the interval between trial completion and commercial launch, bringing new graft designs to market sooner. Each mechanism converts policy into volume: payment rules make procedures financially viable, while user fee timelines accelerate product supply.
Regulatory Barriers and Compliance Costs
The most costly barrier is premarket approval administered by FDA's Center for Devices and Radiological Health under 21 CFR Part 814. Manufacturers must submit pivotal trial data, and analyst estimates place total development cost for a new implantable graft above USD 10 million, with reviews commonly extending beyond 12 months. From February 2, 2026, the Quality Management System Regulation replaces the Quality System Regulation at 21 CFR Part 820, aligning U.S. requirements with ISO 13485:2016 and requiring revised design control and supplier audit systems.
Trade measures create the second barrier. The Commerce Department's Bureau of Industry and Security opened a Section 232 investigation into imported medical devices in September 2025, and any resulting tariffs would raise landed costs for grafts manufactured in Germany, Japan, and Ireland. Third, Open Payments reporting under the Physician Payments Sunshine Act, administered by CMS, requires manufacturers to disclose physician payments, adding compliance cost and audit exposure under the Anti-Kickback Statute.
Policy-Created Opportunities in U.S. Vascular Grafts
The CMS CY2026 Outpatient Prospective Payment System final rule began phasing out the Inpatient Only list, opening peripheral bypass and selected endovascular procedures to ambulatory surgical centers and hospital outpatient departments. Graft suppliers offering compact, pre-packaged ePTFE kits gain volume as site-of-service shifts away from inpatient settings, where bundled DRG payments previously restricted purchasing.
Device pass-through status under Section 1833(t)(6) of the Social Security Act provides separate OPPS payment for qualifying new devices, creating a commercial route for novel endovascular graft designs. Veterans Affairs demand also expands through VA MISSION Act community care referrals, where national contract pricing via Federal Supply Schedule procurement rewards suppliers with validated clinical outcomes data.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 1.12 billion |
| Market Size 2032 | USD 1.78 billion |
| Growth Rate (CAGR) | 6.0% |
| Most Critical Decision Factor | FDA PMA approval timeline and CMS reimbursement classification |
| Largest Region | South (Texas, Florida, Georgia) |
| Competitive Structure | Consolidated; top five suppliers hold roughly 70 percent share |
Leading Market Participants
- W. L. Gore and Associates
- Terumo Aortic
- LeMaitre Vascular
- BD (Bard Peripheral Vascular)
- Medtronic
- Cook Medical
- Getinge
- Artivion
- Bolton Medical
- JOTEC
Regulatory and Policy Environment
The primary legislation is the Federal Food, Drug, and Cosmetic Act of 1938, as amended by the Medical Device Amendments of 1976, which established the device classification system and premarket approval pathway. FDA's Center for Devices and Radiological Health administers compliance, including establishment registration and device listing under 21 CFR Part 807, Unique Device Identification under 21 CFR Part 801, and Medical Device Reporting under 21 CFR Part 803. Cybersecurity requirements under Section 524B, added by the Consolidated Appropriations Act 2023, apply to connected devices.
Upcoming changes include QMSR enforcement from February 2, 2026, MDUFA VI negotiations ahead of the September 2027 expiry of MDUFA V, and the Section 232 trade outcome. Compared with regional peers, the U.S. pathway moves faster than the European Union's Medical Device Regulation (Regulation (EU) 2017/745), where notified body reviews often extend certification beyond a year. Health Canada's Medical Devices Regulations (SOR/98-282) impose comparable evidence demands for implantable grafts but lack an equivalent user fee-driven review timeline.
Long-Term Policy Outlook for Vascular Grafts in the United States
MDUFA VI, negotiated during 2026 and 2027, will set the next performance goals for premarket approval submissions and will determine whether the 180-day review target tightens. CMS will continue shifting peripheral and endovascular procedures toward ambulatory surgical centers as the Inpatient Only list phases out, moving graft purchasing decisions from hospital value committees toward ambulatory and office-based buyers.
Section 232 duties, if imposed, will raise import costs for European and Japanese graft suppliers and accelerate domestic manufacturing investment, including Gore's existing production base in Flagstaff, Arizona. Dialysis access volume will expand as Kidney Care Choices participation grows, with ePTFE access grafts holding share against arteriovenous fistulas wherever vein quality limits fistula creation.
Frequently Asked Questions
Market Segmentation
- Expanded PTFE Grafts
- Polyester (Dacron) Grafts
- Biological and Tissue Grafts
- Endovascular Stent Grafts
- Hybrid Grafts
- Aortic Repair
- Peripheral Bypass
- Hemodialysis Access
- Cerebrovascular Repair
- Hospitals
- Ambulatory Surgical Centers
- Dialysis Clinics
- Veterans Affairs Medical Centers
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.